Y
Yidao Biotechnology
Yidao Biotechnology research and develops vaccines and biomedical products
About Yidao Biotechnology
Yidao Biotechnology (Suzhou) Co., Ltd. is a clinical-stage biopharmaceutical company established in March 2017, focusing on the development and industrialization of innovative human vaccines. The company was founded by a team described as national specially-invited experts and seasoned professionals from the global vaccine and pharmaceutical industries, led by Chairman Shi Li and General Manager Zhi Zhang. The management team brings an average of over 20 years of professional experience, having navigated the vaccine industry's evolution from early growth to periods of rapid technological advancement.
Initially founded in Shanghai's Zhangjiang Pharma Valley, the company signed a strategic cooperation agreement in December 2019 to relocate its headquarters to Suzhou, where it broke ground on a large-scale vaccine industrialization base in 2021. The firm's business model centers on creating and advancing a proprietary pipeline of vaccine candidates to address significant unmet medical needs in infectious diseases and oncology. Its revenue generation will depend on the successful clinical development, regulatory approval, and commercialization of these products.
Yidao's pipeline is spearheaded by two advanced assets: a recombinant zoster (shingles) vaccine using CHO cells, which is in Phase III clinical trials, and a 9-valent recombinant Human Papillomavirus (HPV) vaccine, currently in Phase II trials. The company achieved a significant milestone in July 2020 when it received clinical trial approval for both candidates, with the shingles vaccine being the first of its kind developed by a domestic Chinese company to reach this stage. Its earlier-stage pipeline includes a vaccine for respiratory syncytial virus (RSV) at the IND approval phase, alongside therapeutic vaccines for stomach cancer and COVID-19 in the discovery phase. The company's development is supported by a formidable roster of domestic and international investment funds, including Lilly Asia Ventures, Northern Light Venture Capital, Qiming Venture Partners, OrbiMed, and Sequoia China, secured through multiple financing rounds since 2018.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Suzhou Shi, China
- Open positions
- 5
- Dealroom signal
- 20.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | May 2024 | $25M | $100M | Qiming Venture Partners | — |
| SERIES COther financing | May 2021 | $55M | $220M | Qiming Venture Partners | — |
Growth signals
Latest recorded traffic for Yidao Biotechnology is 40 monthly website visits, down 81.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Yidao Biotechnology in the Suzhou Shi ecosystem
The Yidao Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
NLVC
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Yidao Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Yidao Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










